Eton Pharmaceuticals (ETON) Financials

$17.30 +0.21 (+1.23%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.26 -0.05 (-0.26%)

As of 08/22/2025 04:10 PM Eastern

Annual Income Statements for Eton Pharmaceuticals

This table shows Eton Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-9.02	-0.94	-3.82
Consolidated Net Income / (Loss)	-9.02	-0.94	-3.82
Net Income / (Loss) Continuing Operations	-9.02	-0.94	-3.82
Total Pre-Tax Income	-9.02	-0.69	-3.81
Total Operating Income	-8.26	-1.19	-2.60
Total Gross Profit	14	21	23
Total Revenue	21	32	39
Operating Revenue	21	32	39
Total Cost of Revenue	6.93	11	16
Operating Cost of Revenue	6.93	11	16
Total Operating Expenses	23	22	26
Selling, General & Admin Expense	19	19	23
Research & Development Expense	4.00	3.32	3.26
Total Other Income / (Expense), net	-0.76	0.50	-1.21
Other Income / (Expense), net	-0.76	0.50	-1.21
Income Tax Expense	0.00	0.25	0.02
Basic Earnings per Share	($0.36)	($0.04)	($0.15)
Weighted Average Basic Shares Outstanding	25.15M	25.65M	25.90M
Weighted Average Diluted Shares Outstanding	25.46M	25.69M	26.82M
Weighted Average Basic & Diluted Shares Outstanding	25.46M	25.69M	26.82M

This table shows Eton Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-3.05	0.91	-2.66	4.56	-0.58	-2.26	-0.81	-3.04	0.63	-0.60
Consolidated Net Income / (Loss)	-3.05	0.91	-2.66	4.56	-0.58	-2.26	-0.81	-3.04	0.63	-0.60
Net Income / (Loss) Continuing Operations	-3.05	0.91	-2.66	4.56	-0.58	-2.26	-0.81	-3.04	0.63	-0.60
Total Pre-Tax Income	-3.05	0.91	-2.66	4.56	-0.58	-2.01	-0.81	-2.99	0.50	-0.51
Total Operating Income	-2.90	1.06	-2.53	3.88	-0.55	-1.99	-0.80	-2.94	0.51	0.63
Total Gross Profit	2.02	6.36	3.35	9.68	4.40	3.63	5.01	5.63	6.30	6.48
Total Revenue	3.22	8.50	5.30	12	7.03	7.31	7.97	9.07	10	12
Operating Revenue	3.22	8.50	5.30	12	7.03	7.31	7.97	9.07	10	12
Total Cost of Revenue	1.20	2.14	1.96	2.32	2.63	3.68	2.96	3.45	4.02	5.17
Operating Cost of Revenue	1.20	2.14	1.96	2.32	2.63	3.68	2.96	3.45	4.02	5.17
Total Operating Expenses	4.91	5.30	5.88	5.80	4.95	5.62	5.81	8.56	5.79	5.85
Selling, General & Admin Expense	4.17	4.35	5.35	4.67	4.34	4.58	5.16	5.59	5.29	6.72
Research & Development Expense	0.74	0.94	0.54	1.13	0.62	1.05	0.65	2.97	0.51	-0.87
Total Other Income / (Expense), net	-0.15	-0.15	-0.13	0.68	-0.03	-0.02	-0.01	-0.05	-0.01	-1.14
Other Income / (Expense), net	0.00	-0.52	0.00	0.80	0.00	-0.30	0.00	0.00	0.00	-1.21
Income Tax Expense	0.00	-	0.00	0.00	0.00	0.25	0.00	0.05	-0.13	0.09
Basic Earnings per Share	($0.12)	$209.82	($0.10)	$0.18	($0.02)	($0.10)	($0.03)	($0.12)	$0.02	($0.02)
Weighted Average Basic Shares Outstanding	25.37M	25.15M	25.53M	25.59M	25.72K	25.65M	25.76M	25.78M	25.90K	25.90M
Weighted Average Diluted Shares Outstanding	25.37M	25.46M	25.53M	25.98M	25.72K	25.69M	25.76M	25.78M	26.55K	26.82M
Weighted Average Basic & Diluted Shares Outstanding	25.30M	25.46M	25.50M	25.65M	25.66M	25.69M	25.69M	25.84M	25.84M	26.82M

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	1.90	5.08	-6.45
Net Cash From Operating Activities	4.82	6.82	0.97
Net Cash From Continuing Operating Activities	4.82	6.75	0.97
Net Income / (Loss) Continuing Operations	-9.02	-0.94	-3.82
Consolidated Net Income / (Loss)	-9.02	-0.94	-3.82
Depreciation Expense	1.77	0.90	1.15
Amortization Expense	0.13	0.12	1.11
Non-Cash Adjustments To Reconcile Net Income	5.05	5.96	6.47
Changes in Operating Assets and Liabilities, net	6.89	0.71	-3.94
Net Cash From Investing Activities	-2.79	-0.78	-40
Net Cash From Continuing Investing Activities	-2.79	-0.78	-40
Purchase of Property, Plant & Equipment	-0.04	0.00	-0.03
Acquisitions	-2.75	-0.78	-40
Net Cash From Financing Activities	-0.13	-0.96	33
Net Cash From Continuing Financing Activities	-0.13	-0.96	33
Repayment of Debt	-0.39	-1.16	-1.16
Issuance of Debt	0.00	0.00	25
Issuance of Common Equity	0.17	0.23	7.25
Other Financing Activities, net	0.08	-0.03	1.19
Cash Interest Paid	0.73	0.84	0.67
Cash Income Taxes Paid	0.00	0.25	0.08

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-3.67	2.93	-1.60	6.86	0.50	-0.68	-4.73	1.04	2.57	-5.33
Net Cash From Operating Activities	-1.70	2.84	-1.55	7.10	0.87	0.39	-2.47	1.26	2.95	-0.77
Net Cash From Continuing Operating Activities	-1.70	2.84	-1.55	7.10	0.87	0.32	-2.47	1.26	2.95	-0.77
Net Income / (Loss) Continuing Operations	-3.05	0.91	-2.66	4.56	-0.58	-2.26	-0.81	-3.04	0.63	-0.60
Consolidated Net Income / (Loss)	-3.05	0.91	-2.66	4.56	-0.58	-2.26	-0.81	-3.04	0.63	-0.60
Depreciation Expense	0.17	0.25	0.21	0.17	0.19	0.33	0.25	0.26	0.28	0.36
Amortization Expense	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	1.04
Non-Cash Adjustments To Reconcile Net Income	0.95	1.72	0.87	0.82	3.08	1.18	0.82	0.88	5.16	-0.38
Changes in Operating Assets and Liabilities, net	0.19	-0.07	-0.00	1.52	-1.85	1.05	-2.76	3.14	-3.13	-1.18
Net Cash From Investing Activities	-2.00	-0.01	0.00	-	-	-0.78	-1.88	-	-	-38
Net Cash From Continuing Investing Activities	-2.00	-0.01	0.00	-	-	-0.78	-1.88	-	-	-38
Purchase of Property, Plant & Equipment	-	-0.01	0.00	-	-	-	-0.01	-	-	-0.01
Acquisitions	-2.00	-	0.00	-	-	-0.78	-1.87	-	-	-38
Net Cash From Financing Activities	0.04	0.10	-0.05	-0.25	-0.37	-0.29	-0.38	-0.22	-0.39	34
Net Cash From Continuing Financing Activities	0.04	0.10	-0.05	-0.25	-0.37	-0.29	-0.38	-0.22	-0.39	34
Other Financing Activities, net	0.04	-0.07	-0.05	0.14	0.02	-0.14	0.01	0.17	-	1.02
Cash Interest Paid	0.17	0.19	0.22	0.21	0.21	0.20	0.19	0.17	0.16	0.14
Cash Income Taxes Paid	-	-	0.00	-	-	0.25	0.00	-	0.18	-0.10

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	25	32	76
Total Current Assets	20	27	41
Cash & Equivalents	16	21	15
Accounts Receivable	1.85	3.41	5.36
Inventories, net	0.56	0.91	15
Prepaid Expenses	1.29	1.13	5.49
Plant, Property, & Equipment, net	0.07	0.06	0.03
Total Noncurrent Assets	4.95	4.84	35
Intangible Assets	4.75	4.74	35
Other Noncurrent Operating Assets	0.20	0.10	0.19
Total Liabilities & Shareholders' Equity	25	32	76
Total Liabilities	12	16	52
Total Current Liabilities	6.46	16	20
Short-Term Debt	1.03	5.38	0.00
Accounts Payable	1.77	1.85	4.17
Accrued Expenses	3.66	9.01	16
Total Noncurrent Liabilities	5.49	0.02	32
Long-Term Debt	5.38	0.00	30
Other Noncurrent Operating Liabilities	0.11	0.02	1.94
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	13	15	24
Total Preferred & Common Equity	13	15	24
Total Common Equity	13	15	24
Common Stock	116	120	132
Retained Earnings	-103	-104	-108

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	22	24	31	32	31	32	36
Total Current Assets	16	19	26	27	24	25	30
Cash & Equivalents	13	15	22	22	17	18	20
Accounts Receivable	1.50	2.87	3.08	3.50	4.24	4.87	5.59
Inventories, net	0.48	0.44	0.82	1.05	2.32	2.07	1.94
Prepaid Expenses	1.06	1.10	0.87	0.54	1.05	0.80	1.96
Plant, Property, & Equipment, net	0.07	0.06	0.05	0.04	0.06	0.05	0.03
Total Noncurrent Assets	5.03	4.75	4.55	4.33	6.47	6.34	6.06
Intangible Assets	4.97	4.57	4.39	4.21	6.39	6.12	5.85
Other Noncurrent Operating Assets	0.05	0.18	0.16	0.12	0.09	0.22	0.21
Total Liabilities & Shareholders' Equity	22	24	31	32	31	32	36
Total Liabilities	10	13	14	15	15	18	20
Total Current Liabilities	4.66	7.49	9.59	10	15	18	20
Short-Term Debt	0.71	1.34	1.54	1.54	5.02	4.66	4.13
Accounts Payable	1.05	1.23	2.30	1.71	2.26	2.13	2.68
Accrued Expenses	2.90	4.92	5.75	7.14	8.02	11	13
Total Noncurrent Liabilities	5.68	5.19	4.62	4.24	0.00	0.15	0.13
Other Noncurrent Operating Liabilities	-	0.09	0.07	0.04	0.00	0.15	0.13
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	11	11	17	17	15	13	16
Total Preferred & Common Equity	11	11	17	17	15	13	16
Total Common Equity	11	11	17	17	15	13	16
Common Stock	115	117	118	119	120	121	123
Retained Earnings	-104	-106	-101	-102	-105	-108	-107

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-2.66%	48.90%	23.29%
EBITDA Growth	-316.37%	104.62%	-572.04%
EBIT Growth	-288.84%	92.36%	-452.69%
NOPAT Growth	-452.51%	85.57%	-117.87%
Net Income Growth	-361.43%	89.62%	-308.44%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	202.12%	41.36%	-85.78%
Free Cash Flow Firm Growth	109.49%	209.72%	-1,542.94%
Invested Capital Growth	-67.79%	-116.65%	7,501.69%
Revenue Q/Q Growth	12.76%	-3.61%	12.50%
EBITDA Q/Q Growth	-5.75%	-89.37%	63.91%
EBIT Q/Q Growth	-5.81%	-132.12%	30.96%
NOPAT Q/Q Growth	-3.15%	-144.79%	50.24%
Net Income Q/Q Growth	-1.43%	-141.94%	30.25%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	253.73%	-26.47%	-54.31%
Free Cash Flow Firm Q/Q Growth	109.14%	-47.45%	-1,317.07%
Invested Capital Q/Q Growth	-23.85%	-194.99%	25,456.77%
Profitability Metrics	-	-	-
Gross Margin	67.38%	66.56%	60.01%
EBITDA Margin	-33.50%	1.04%	-3.98%
Operating Margin	-38.87%	-3.77%	-6.66%
EBIT Margin	-42.45%	-2.18%	-9.76%
Profit (Net Income) Margin	-42.45%	-2.96%	-9.80%
Tax Burden Percent	100.00%	135.85%	100.39%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-88.32%	-62.76%	-9.38%
ROIC Less NNEP Spread (ROIC-NNEP)	-51.54%	-61.98%	344.57%
Return on Net Nonoperating Assets (RNNOA)	29.56%	56.20%	-9.78%
Return on Equity (ROE)	-58.75%	-6.56%	-19.16%
Cash Return on Invested Capital (CROIC)	14.24%	0.00%	-105.98%
Operating Return on Assets (OROA)	-34.37%	-2.43%	-7.06%
Return on Assets (ROA)	-34.37%	-3.30%	-7.09%
Return on Common Equity (ROCE)	-58.75%	-6.56%	-19.16%
Return on Equity Simple (ROE_SIMPLE)	-68.98%	-6.05%	-15.65%
Net Operating Profit after Tax (NOPAT)	-5.78	-0.83	-1.82
NOPAT Margin	-27.21%	-2.64%	-4.66%
Net Nonoperating Expense Percent (NNEP)	-36.78%	-0.78%	-353.95%
Return On Investment Capital (ROIC_SIMPLE)	-29.66%	-4.00%	-3.35%
Cost of Revenue to Revenue	32.62%	33.44%	39.99%
SG&A Expenses to Revenue	87.44%	59.83%	58.32%
R&D to Revenue	18.80%	10.50%	8.34%
Operating Expenses to Revenue	106.24%	70.33%	66.67%
Earnings before Interest and Taxes (EBIT)	-9.02	-0.69	-3.81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.12	0.33	-1.55
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	5.45	7.26	14.09
Price to Tangible Book Value (P/TBV)	8.57	10.47	0.00
Price to Revenue (P/Rev)	3.36	3.55	8.82
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.26	0.00	9.13
Enterprise Value to Revenue (EV/Rev)	2.89	3.05	9.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	292.94	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.75	14.14	370.50
Enterprise Value to Free Cash Flow (EV/FCFF)	65.93	33.39	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.49	0.35	1.22
Long-Term Debt to Equity	0.41	0.00	1.22
Financial Leverage	-0.57	-0.91	-0.03
Leverage Ratio	1.71	1.99	2.70
Compound Leverage Factor	1.71	1.99	2.70
Debt to Total Capital	32.92%	25.79%	54.96%
Short-Term Debt to Total Capital	5.30%	25.79%	0.00%
Long-Term Debt to Total Capital	27.62%	0.00%	54.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.08%	74.21%	45.04%
Debt to EBITDA	-0.90	16.35	-19.20
Net Debt to EBITDA	1.39	-48.66	-9.58
Long-Term Debt to EBITDA	-0.76	0.00	-19.20
Debt to NOPAT	-1.11	-6.45	-16.40
Net Debt to NOPAT	1.71	19.19	-8.18
Long-Term Debt to NOPAT	-0.93	0.00	-16.40
Altman Z-Score	-1.88	0.88	2.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.10	1.65	2.06
Quick Ratio	2.81	1.53	1.02
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.93	2.89	-42
Operating Cash Flow to CapEx	12,686.84%	0.00%	3,726.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.81	1.11	0.72
Accounts Receivable Turnover	5.80	12.02	8.89
Inventory Turnover	12.53	14.42	1.93
Fixed Asset Turnover	227.28	486.80	848.07
Accounts Payable Turnover	3.92	5.86	5.19
Days Sales Outstanding (DSO)	62.89	30.36	41.04
Days Inventory Outstanding (DIO)	29.14	25.32	188.85
Days Payable Outstanding (DPO)	93.18	62.33	70.37
Cash Conversion Cycle (CCC)	-1.16	-6.66	159.52
Capital & Investment Metrics	-	-	-
Invested Capital	3.19	-0.53	39
Invested Capital Turnover	3.25	23.80	2.01
Increase / (Decrease) in Invested Capital	-6.71	-3.72	40
Enterprise Value (EV)	61	96	359
Market Capitalization	71	112	344
Book Value per Share	$0.52	$0.60	$0.95
Tangible Book Value per Share	$0.33	$0.42	($0.40)
Total Capital	19	21	54
Total Debt	6.42	5.38	30
Total Long-Term Debt	5.38	0.00	30
Net Debt	-9.89	-16	15
Capital Expenditures (CapEx)	0.04	0.00	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.73	-5.41	6.14
Debt-free Net Working Capital (DFNWC)	15	16	21
Net Working Capital (NWC)	14	11	21
Net Nonoperating Expense (NNE)	3.24	0.10	2.01
Net Nonoperating Obligations (NNO)	-9.89	-16	15
Total Depreciation and Amortization (D&A)	1.90	1.02	2.26
Debt-free, Cash-free Net Working Capital to Revenue	-8.14%	-17.10%	15.73%
Debt-free Net Working Capital to Revenue	68.59%	50.50%	54.02%
Net Working Capital to Revenue	63.73%	33.49%	54.02%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.36)	($0.04)	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	25.15M	25.65M	25.90M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	25.46M	25.69M	26.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.46M	25.69M	26.82M
Normalized Net Operating Profit after Tax (NOPAT)	-5.78	-0.83	-1.82
Normalized NOPAT Margin	-27.21%	-2.64%	-4.66%
Pre Tax Income Margin	-42.45%	-2.18%	-9.76%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	315.35%	39.47%	143.75%	63.05%	118.33%	-13.94%	50.19%	-24.36%	46.90%	59.26%
EBITDA Growth	54.87%	-31.88%	55.17%	3,615.83%	87.83%	-334.34%	77.18%	-154.25%	346.65%	141.90%
EBIT Growth	52.49%	-47.64%	52.46%	449.48%	81.07%	-520.96%	68.43%	-162.67%	192.88%	74.59%
NOPAT Growth	50.49%	-19.18%	50.19%	513.97%	81.07%	-231.37%	68.43%	-152.91%	266.06%	131.56%
Net Income Growth	50.03%	-12.22%	50.09%	392.62%	80.99%	-347.37%	69.51%	-166.70%	208.29%	73.49%
EPS Growth	50.00%	0.00%	0.00%	400.00%	83.33%	0.00%	70.00%	-166.67%	200.00%	0.00%
Operating Cash Flow Growth	42.27%	155.50%	-226.57%	188.62%	151.26%	-86.37%	-59.75%	-82.33%	238.14%	-297.67%
Free Cash Flow Firm Growth	-152.49%	204.25%	94.72%	387.78%	149.02%	-70.09%	-437.71%	-123.70%	-58.38%	-1,793.70%
Invested Capital Growth	1,129.24%	-67.79%	-33.58%	-50.94%	-86.66%	-116.65%	29.54%	-65.97%	-127.73%	7,501.69%
Revenue Q/Q Growth	-56.25%	164.00%	-37.59%	126.19%	-41.42%	4.06%	8.93%	13.91%	13.78%	12.81%
EBITDA Q/Q Growth	-1,838.85%	130.69%	-377.15%	313.22%	-106.71%	-490.85%	73.69%	-406.88%	130.52%	0.37%
EBIT Q/Q Growth	-116.04%	118.79%	-565.81%	284.81%	-111.70%	-317.88%	65.07%	-266.88%	117.34%	-214.34%
NOPAT Q/Q Growth	-116.04%	152.41%	-267.02%	318.91%	-109.88%	-263.69%	59.86%	-266.88%	131.01%	-30.88%
Net Income Q/Q Growth	-95.44%	129.95%	-391.67%	271.39%	-112.70%	-289.64%	64.05%	-274.97%	120.62%	-195.37%
EPS Q/Q Growth	-100.00%	0.00%	0.00%	280.00%	-111.11%	0.00%	0.00%	-300.00%	116.67%	0.00%
Operating Cash Flow Q/Q Growth	-169.20%	266.76%	-154.51%	558.85%	-87.71%	-55.67%	-739.02%	150.75%	135.22%	-125.91%
Free Cash Flow Firm Q/Q Growth	-267.71%	217.42%	-103.44%	2,035.40%	-37.36%	-28.35%	-161.91%	14.69%	209.97%	-3,015.87%
Invested Capital Q/Q Growth	64.15%	-23.85%	-6.61%	-57.97%	-55.35%	-194.99%	826.74%	-88.96%	-136.39%	25,456.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	62.69%	74.84%	63.08%	80.70%	62.65%	49.64%	62.85%	62.00%	61.04%	55.60%
EBITDA Margin	-83.72%	9.73%	-43.21%	40.74%	-4.67%	-26.50%	-6.57%	-29.22%	7.84%	6.97%
Operating Margin	-89.93%	12.50%	-47.78%	32.37%	-7.80%	-27.25%	-10.04%	-32.35%	4.93%	5.40%
EBIT Margin	-89.93%	6.40%	-47.78%	39.03%	-7.80%	-31.31%	-10.04%	-32.35%	4.93%	-5.00%
Profit (Net Income) Margin	-94.59%	10.73%	-50.15%	38.00%	-8.24%	-30.85%	-10.18%	-33.51%	6.07%	-5.13%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	112.29%	100.00%	101.81%	125.15%	117.03%
Interest Burden Percent	105.18%	167.65%	104.97%	97.35%	105.66%	87.73%	101.38%	101.77%	98.43%	87.80%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-25.15%	0.00%
Return on Invested Capital (ROIC)	-627.41%	40.56%	-218.46%	493.80%	-75.47%	-454.03%	-70.53%	-846.86%	1,059.23%	7.61%
ROIC Less NNEP Spread (ROIC-NNEP)	-618.58%	42.27%	-208.13%	488.63%	-73.80%	-447.38%	-68.01%	-839.94%	1,059.29%	190.89%
Return on Net Nonoperating Assets (RNNOA)	531.42%	-24.24%	145.04%	-426.61%	61.32%	405.72%	50.62%	793.25%	-1,046.27%	-5.42%
Return on Equity (ROE)	-95.99%	16.32%	-73.42%	67.19%	-14.16%	-48.31%	-19.92%	-53.61%	12.96%	2.19%
Cash Return on Invested Capital (CROIC)	-243.53%	14.24%	-66.69%	50.54%	231.38%	0.00%	-13.26%	-425.17%	0.00%	-105.98%
Operating Return on Assets (OROA)	-70.44%	5.18%	-49.43%	41.97%	-9.65%	-34.91%	-12.59%	-32.35%	5.08%	-3.61%
Return on Assets (ROA)	-74.09%	8.69%	-51.89%	40.86%	-10.20%	-34.39%	-12.76%	-33.52%	6.25%	-3.71%
Return on Common Equity (ROCE)	-95.99%	16.32%	-73.42%	67.19%	-14.16%	-48.31%	-19.92%	-53.61%	12.96%	2.19%
Return on Equity Simple (ROE_SIMPLE)	-79.55%	0.00%	-56.50%	-1.40%	13.21%	0.00%	5.89%	-49.67%	-34.30%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.03	1.06	-1.77	3.88	-0.38	-1.40	-0.56	-2.05	0.64	0.44
NOPAT Margin	-62.95%	12.50%	-33.44%	32.37%	-5.46%	-19.08%	-7.03%	-22.64%	6.17%	3.78%
Net Nonoperating Expense Percent (NNEP)	-8.83%	-1.70%	-10.33%	5.17%	-1.68%	-6.65%	-2.52%	-6.92%	-0.06%	-183.28%
Return On Investment Capital (ROIC_SIMPLE)	-	5.45%	-	-	-	-6.69%	-	-	-	0.81%
Cost of Revenue to Revenue	37.31%	25.16%	36.92%	19.30%	37.35%	50.36%	37.15%	38.00%	38.96%	44.40%
SG&A Expenses to Revenue	129.51%	51.24%	100.77%	38.96%	61.70%	62.57%	64.73%	61.62%	51.22%	57.68%
R&D to Revenue	23.11%	11.11%	10.09%	9.38%	8.75%	14.32%	8.17%	32.73%	4.89%	-7.48%
Operating Expenses to Revenue	152.63%	62.34%	110.86%	48.34%	70.45%	76.89%	72.90%	94.35%	56.11%	50.20%
Earnings before Interest and Taxes (EBIT)	-2.90	0.54	-2.53	4.68	-0.55	-2.29	-0.80	-2.94	0.51	-0.58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.70	0.83	-2.29	4.89	-0.33	-1.94	-0.52	-2.65	0.81	0.81
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.75	5.45	8.72	5.32	6.33	7.26	6.22	6.28	9.70	14.09
Price to Tangible Book Value (P/TBV)	8.56	8.57	14.70	7.22	8.44	10.47	10.58	11.52	15.31	0.00
Price to Revenue (P/Rev)	2.82	3.36	4.02	3.07	3.26	3.55	2.81	2.69	4.47	8.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	47.93	0.00	105.51	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	2.09%	0.00%	0.95%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.01	19.26	30.13	58.74	162.15	0.00	21.95	167.81	0.00	9.13
Enterprise Value to Revenue (EV/Rev)	2.45	2.89	3.68	2.53	2.76	3.05	2.47	2.28	4.01	9.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	101.15	29.30	292.94	40.37	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	42.26	0.00	81.05	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	48.65	0.00	198.54	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	12.75	43.78	10.99	9.78	14.14	14.38	1,702.05	65.48	370.50
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	65.93	0.00	76.51	16.50	33.39	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.57	0.49	0.57	0.36	0.34	0.35	0.32	0.35	0.26	1.22
Long-Term Debt to Equity	0.51	0.41	0.45	0.27	0.25	0.00	0.00	0.00	0.00	1.22
Financial Leverage	-0.86	-0.57	-0.70	-0.87	-0.83	-0.91	-0.74	-0.94	-0.99	-0.03
Leverage Ratio	1.79	1.71	1.91	1.80	1.89	1.99	2.05	2.08	2.05	2.70
Compound Leverage Factor	1.89	2.87	2.01	1.75	2.00	1.74	2.08	2.12	2.02	2.37
Debt to Total Capital	36.35%	32.92%	36.44%	26.70%	25.35%	25.79%	24.47%	25.71%	20.52%	54.96%
Short-Term Debt to Total Capital	4.03%	5.30%	7.57%	6.75%	6.81%	25.79%	24.47%	25.71%	20.52%	0.00%
Long-Term Debt to Total Capital	32.32%	27.62%	28.87%	19.95%	18.55%	0.00%	0.00%	0.00%	0.00%	54.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.65%	67.08%	63.56%	73.30%	74.65%	74.21%	75.53%	74.29%	79.48%	45.04%
Debt to EBITDA	-0.95	-0.90	-1.50	8.38	1.85	16.35	2.39	-0.86	-0.96	-19.20
Net Debt to EBITDA	1.04	1.39	1.92	-21.28	-5.28	-48.66	-5.55	2.40	3.75	-9.58
Long-Term Debt to EBITDA	-0.84	-0.76	-1.19	6.26	1.36	0.00	0.00	0.00	0.00	-19.20
Debt to NOPAT	-1.14	-1.11	-1.61	-17.98	3.08	-6.45	11.77	-1.06	-1.13	-16.40
Net Debt to NOPAT	1.25	1.71	2.07	45.67	-8.77	19.19	-27.27	2.97	4.42	-8.18
Long-Term Debt to NOPAT	-1.01	-0.93	-1.28	-13.44	2.25	0.00	0.00	0.00	0.00	-16.40
Altman Z-Score	-2.60	-0.62	-0.30	1.26	1.49	0.72	0.39	-1.03	1.84	2.83
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.52	3.10	2.55	2.75	2.61	1.65	1.59	1.40	1.51	2.06
Quick Ratio	3.19	2.81	2.35	2.57	2.46	1.53	1.37	1.24	1.31	1.02
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.62	7.78	-0.27	5.18	3.25	2.33	-1.44	-1.23	1.35	-39
Operating Cash Flow to CapEx	0.00%	23,666.67%	0.00%	0.00%	0.00%	0.00%	-17,664.29%	0.00%	0.00%	-6,375.00%
Free Cash Flow to Firm to Interest Expense	-44.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-11.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-11.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.78	0.81	1.03	1.08	1.24	1.11	1.25	1.00	1.03	0.72
Accounts Receivable Turnover	20.02	5.80	13.29	14.81	13.15	12.02	9.64	7.89	7.63	8.89
Inventory Turnover	12.77	12.53	16.98	11.30	11.80	14.42	8.41	8.82	9.44	1.93
Fixed Asset Turnover	182.09	227.28	295.50	436.36	591.48	486.80	607.15	689.69	976.82	848.07
Accounts Payable Turnover	2.41	3.92	4.78	4.23	6.53	5.86	6.63	5.74	6.42	5.19
Days Sales Outstanding (DSO)	18.23	62.89	27.47	24.64	27.76	30.36	37.85	46.27	47.82	41.04
Days Inventory Outstanding (DIO)	28.58	29.14	21.49	32.29	30.94	25.32	43.41	41.39	38.65	188.85
Days Payable Outstanding (DPO)	151.74	93.18	76.34	86.29	55.86	62.33	55.09	63.63	56.85	70.37
Cash Conversion Cycle (CCC)	-104.93	-1.16	-27.38	-29.35	2.84	-6.66	26.17	24.04	29.62	159.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	4.19	3.19	2.98	1.25	0.56	-0.53	3.86	0.43	-0.16	39
Invested Capital Turnover	9.97	3.25	6.53	15.26	13.83	23.80	10.03	37.40	171.67	2.01
Increase / (Decrease) in Invested Capital	4.60	-6.71	-1.51	-1.30	-3.63	-3.72	0.88	-0.83	-0.71	40
Enterprise Value (EV)	46	61	90	74	91	96	85	71	139	359
Market Capitalization	53	71	98	89	107	112	96	85	155	344
Book Value per Share	$0.44	$0.52	$0.44	$0.66	$0.66	$0.60	$0.60	$0.52	$0.62	$0.95
Tangible Book Value per Share	$0.25	$0.33	$0.26	$0.48	$0.49	$0.42	$0.35	$0.29	$0.39	($0.40)
Total Capital	18	19	18	23	23	21	21	18	20	54
Total Debt	6.39	6.42	6.45	6.09	5.74	5.38	5.02	4.66	4.13	30
Total Long-Term Debt	5.68	5.38	5.11	4.55	4.20	0.00	0.00	0.00	0.00	30
Net Debt	-6.99	-9.89	-8.26	-15	-16	-16	-12	-13	-16	15
Capital Expenditures (CapEx)	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.91	-1.73	-1.75	-3.28	-3.77	-5.41	-2.67	-5.82	-6.12	6.14
Debt-free Net Working Capital (DFNWC)	12	15	13	18	18	16	14	12	14	21
Net Working Capital (NWC)	12	14	12	17	17	11	8.96	7.22	10	21
Net Nonoperating Expense (NNE)	1.02	0.15	0.89	-0.68	0.20	0.86	0.25	0.99	0.01	1.04
Net Nonoperating Obligations (NNO)	-6.99	-9.89	-8.26	-15	-16	-16	-12	-13	-16	15
Total Depreciation and Amortization (D&A)	0.20	0.28	0.24	0.20	0.22	0.35	0.28	0.28	0.30	1.39
Debt-free, Cash-free Net Working Capital to Revenue	-4.83%	-8.14%	-7.16%	-11.31%	-11.47%	-17.10%	-7.79%	-18.54%	-17.65%	15.73%
Debt-free Net Working Capital to Revenue	66.15%	68.59%	53.17%	63.01%	55.76%	50.50%	40.76%	37.84%	40.78%	54.02%
Net Working Capital to Revenue	62.40%	63.73%	47.68%	57.71%	51.07%	33.49%	26.13%	23.00%	28.88%	54.02%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.12)	$209.82	($100.00)	$0.18	($0.02)	($0.10)	($0.03)	($0.12)	$0.02	($0.02)
Adjusted Weighted Average Basic Shares Outstanding	25.37M	25.15M	25.53M	25.59M	25.72M	25.65M	25.76M	25.78M	25.90K	25.90M
Adjusted Diluted Earnings per Share	($0.12)	$0.00	$0.00	$0.18	($0.02)	$0.00	($0.03)	($0.12)	$0.02	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	25.37M	25.46M	25.50M	25.98M	25.72M	25.69M	25.76M	25.78M	26.55K	26.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.30M	25.46M	25.50M	25.65M	25.66M	25.69M	25.69M	25.84M	25.84M	26.82M
Normalized Net Operating Profit after Tax (NOPAT)	-2.03	0.74	-1.77	2.72	-0.38	-1.40	-0.56	-2.05	0.36	0.44
Normalized NOPAT Margin	-62.95%	8.75%	-33.44%	22.66%	-5.46%	-19.08%	-7.03%	-22.64%	3.45%	3.78%
Pre Tax Income Margin	-94.59%	10.73%	-50.15%	38.00%	-8.24%	-27.47%	-10.18%	-32.92%	4.85%	-4.39%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-19.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-13.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-19.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-13.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

The financial data for Eton Pharmaceuticals (NASDAQ: ETON) over the last four years reveals several key trends in revenues, profitability, cash flows, and financial position. Below is a summary of the most important aspects that can help retail investors understand the company's recent financial performance:

Operating revenue has grown significantly from about $3.2 million in Q3 2022 to $11.6 million in Q4 2024, reflecting strong top-line growth and likely improved market presence.
Gross profit has increased steadily, with Q4 2024 gross profit reaching approximately $6.5 million compared to $2.0 million in Q3 2022, indicating an improving product margin over time.
Eton’s total assets rose from about $21.5 million in Q3 2022 to over $35.8 million by Q3 2024, benefiting from acquisitions and asset growth, supporting long-term capacity expansion.
Cash and equivalents increased from $13.4 million in Q3 2022 to around $20.3 million in Q3 2024, providing a stronger liquidity position for operations and investments.
The company reduced long-term and short-term debt moderately from 2022 to 2024, indicating some deleveraging efforts and potentially lower financial risk.
Operating expenses have fluctuated over the period, with increases in SG&A and R&D spending, reflecting ongoing investments in growth and product development.
Eton completed substantial acquisitions in 2024 (e.g., $38 million outlay in Q4 2024), which could either fuel future growth or strain cash flows depending on integration success.
Net income has shown volatility, swinging from losses in early 2023 quarters to small profits by mid-2023, then back to losses by Q4 2024, indicating ongoing profitability challenges.
Depreciation and amortization expenses increased significantly in recent periods, often associated with intangible assets from acquisitions, impacting net income but less so cash flows.
The company reported a net loss of approximately $598,000 in Q4 2024, continuing a pattern of net losses in several recent quarters, suggesting the company has not yet fully achieved sustained profitability.
Operating cash flow was negative in Q4 2024 (-$765,000), signaling cash burn from operations in the most recent quarter, which can pressure liquidity if prolonged.
Total operating expenses and SG&A costs remain high relative to revenue, which compresses operating income and profitability potential, as seen by operating income of only $629,000 in Q4 2024 on $11.6 million of revenue.
Other income/expense items have worsened, with significant negative impacts (-$1.14 million in Q4 2024), reducing pre-tax income and net profit.

Overall, Eton Pharmaceuticals has demonstrated substantial revenue growth and balance sheet expansion over the past two years, underpinned by acquisitions and increased asset base. However, the company continues to face profitability challenges, with irregular net income results and negative cash flow from operations in the most recent quarter. Investors should watch closely how management controls costs, integrates acquisitions, and converts revenue growth into sustained profit and positive operating cash flow moving forward.

08/23/25 11:22 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Eton Pharmaceuticals' Financials

When does Eton Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Eton Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Eton Pharmaceuticals' net income changed over the last 2 years?

Eton Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$3.82 million in 2024, falling from -$9.02 million in 2022. The previous period was -$936 thousand in 2023. See where experts think Eton Pharmaceuticals is headed by visiting Eton Pharmaceuticals' forecast page.

What is Eton Pharmaceuticals' operating income?

Eton Pharmaceuticals' total operating income in 2024 was -$2.60 million, based on the following breakdown:

Total Gross Profit: $23.41 million
Total Operating Expenses: $26.01 million

How has Eton Pharmaceuticals' revenue changed over the last 2 years?

Over the last 2 years, Eton Pharmaceuticals' total revenue changed from $21.25 million in 2022 to $39.01 million in 2024, a change of 83.6%.

How much debt does Eton Pharmaceuticals have?

Eton Pharmaceuticals' total liabilities were at $51.70 million at the end of 2024, a 217.9% increase from 2023, and a 332.5% increase since 2022.

How much cash does Eton Pharmaceuticals have?

In the past 2 years, Eton Pharmaceuticals' cash and equivalents has ranged from $14.94 million in 2024 to $21.39 million in 2023, and is currently $14.94 million as of their latest financial filing in 2024.

How has Eton Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Eton Pharmaceuticals' book value per share changed from 0.52 in 2022 to 0.95 in 2024, a change of 82.9%.

Related Companies

This page (NASDAQ:ETON) was last updated on 8/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Financials

Key Financial Trends

Frequently Asked Questions About Eton Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Financials

Annual Income Statements for Eton Pharmaceuticals

Quarterly Income Statements for Eton Pharmaceuticals

Annual Cash Flow Statements for Eton Pharmaceuticals

Quarterly Cash Flow Statements for Eton Pharmaceuticals

Annual Balance Sheets for Eton Pharmaceuticals

Quarterly Balance Sheets for Eton Pharmaceuticals

Annual Metrics And Ratios for Eton Pharmaceuticals

Quarterly Metrics And Ratios for Eton Pharmaceuticals

Key Financial Trends

Frequently Asked Questions About Eton Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools